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The comprehensive genetic characterisation of human
tumours promises to contribute a profound understand-
ing of the changes that contribute to and drive the
oncogenic process. In one study, we have been able to
determine the oncogenic mechanisms driving a rare
adenocarcinoma of the tongue and provide clinically
useful information to aid in its treatment, through the
determination that the cancer was driven primarily by
activation of the RET pathway. The administration of
RET targeting kinase inhibitors, sunitinib and sorafenib,
provided tumour stabilisation for several months, after
which time therapeutic resistant tumours arose. This
provided us with the opportunity to identify the genetic
changes associated with drug resistance allowing the
observation that resistance is correlated with an appar-
ent up-regulation of the parallel proliferative AKT
pathway.
However, the complete and comprehensive analysis of
a genome using this technology is still nascent and
many of the software tools required to achieve this are
still in development. In the analysis of tumour normal
pairs, it is not clear that current levels of sampling are
sufficient to identify somatic changes accurately without
further validation. Likewise, the level of false negatives
that confound our analyses is unclear. Such considera-
tions will be important if this technology is to be
adopted in the routine provision of personalized
medicine.
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